Boston Scientific Pursues Cost Cutting, Asset Sales
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific plans to cut costs to address the reality that its core implantable defibrillator and drug-eluting stent businesses have not rebounded as predicted at the beginning of the year